Relay Therapeutics (RLAY) Director Linda A. Hill Receives Stock Award

What Happened Linda A. Hill, a director of Relay Therapeutics, was granted a derivative award (option) covering 32,947 shares of the company's common stock on June 9, 2026. The reported acquisition price is $0.00 (a grant/award rather than an open‑market purchase or sale). The award vests in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders (see footnote).

Key Details

• Transaction date: 2026-06-09; filing date: 2026-06-10 (timely filing).
• Transaction type/code: Grant/Award (Form 4 code A); 32,947 derivative shares; $0.00 reported consideration.
• Vesting: Vests in full on the earlier of (a) one year from grant or (b) the next annual meeting (footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Other notes: This is a grant of an option/derivative interest (not an immediate cash transaction or sale). No 10b5-1 plan, tax‑withholding sale, or late filing flag noted in the excerpt.

Context This grant is a common form of director compensation intended to align long‑term interests with shareholders; it does not represent an open‑market purchase or an immediate cash realization. If the option is later exercised or shares are sold, those events would generate additional Form 4 filings.